Access cutting-edge common variable immunodeficiency treatment through this clinical trial at a research site in Burlington. Study-provided care at no cost to qualified participants.
Access common variable immunodeficiency specialists in Burlington at no cost
This study follows strict safety protocols and ethical guidelines
All study-related common variable immunodeficiency treatment provided free
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Fu
Sponsor: Children's Hospital Medical Center, Cincinnati
Check if you qualify for this common variable immunodeficiency clinical trial in Burlington, MA
If you're searching for common variable immunodeficiency treatment options in Burlington, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Burlington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced common variable immunodeficiency specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.